AGA Medical Corporation

AGA Medical Corporation specializes in advanced cardiac devices, focusing on minimally invasive treatments for structural heart diseases, particularly through innovative occluders and delivery systems. Founded in 1995 and headquartered in Plymouth, US, AGA Medical Corporation develops medical devices to treat structural heart conditions. The company underwent a significant transition when it was acquired by St. Jude Medical in October 2010 for approximately USD 1.

08 bn. AGA Medical previously raised USD 199. 4 mn in its IPO in October 2009, with Welsh Carson Anderson holding a majority stake thereafter. AGA Medical Corporation's primary offerings include advanced cardiac devices tailored for minimally invasive procedures.

Their product line consists of occluders and delivery systems effective for addressing atrial septal defects and patent foramen ovale, aimed at improving closure outcomes in heart defects. These devices cater to healthcare providers, including hospitals and specialized cardiac clinics, across global markets such as North America, Europe, and select regions in Asia-Pacific. In the most recent year, AGA Medical Corporation reported a revenue of USD 198. 71 mn in 2009, with an EBITDA of USD 39.

60 mn for the same year. The revenue model is built on direct sales to hospitals and health systems, supported by partnerships and distribution networks, often including training and support contracts. The company is focusing on launching new cardiac devices and expanding its market presence. With the recent acquisition by St.

Jude Medical, AGA Medical plans to leverage its resources to enhance product development. The company aims to penetrate emerging markets in Asia-Pacific by 2012, utilizing the capital from its latest round of funding, which was concluded in October 2010, to support these initiatives.